CTOs on the Move

Azerion

www.azerion.com

 
Azerion is a high-growth digital entertainment and media platform. As a content-driven, technology and data company, Azerion serves consumers, digital publishers, advertisers, and game creators globally.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million
  • www.azerion.com
  • One World Trade Center, 285 Fulton Street 46th Floor, Suite J
    New York, NY USA 10007
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Hopin

Engaging online events that people love. Hopin is an all-in-one virtual event management software platform for managing events and experiences.

DerbySoft

Founded in 2002, DerbySoft Inc., provides a broad range of distribution services to the hospitality industry. All of the worlds largest hotel groups, online travel agencies, and metasearch engines rely on DerbySoft, and were now leveraging our knowl...

SIEMonster

SIEMonster is an Enterprise-grade Security Information and Event Management (SIEM), built on scalable, open source components.

Symphony SummitAI

Re-imagine IT Management with SummitAI, an AI-driven IT Management suite. Unleash enterprise productivity by effortlessly bringing Service, Asset and Operations Management together to work in concert. SummitAI uses machine reasoning and codeless workflow based automation, delivers up to 20% annual savings in IT Help Desk Operations, and up to 45% better Total Cost of Ownership.

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.